<DOC>
	<DOC>NCT01820572</DOC>
	<brief_summary>The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.</brief_summary>
	<brief_title>A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Men and women, ages 1875 inclusive Adult recipients of a renal allograft from a living donor or a deceased donor between 660 months prior to enrollment Receiving a stable (≥1 month) regimen of Calcineurin inhibitor (CNI) [Cyclosporine A (CsA) or Tacrolimus (TAC)] with Mycophenolate mofetil (MMF) or Enteric Coated Mycophenolate Sodium (ECMPS)/Mycophenolic acid (MPA), and corticosteroids Stable renal function for 12 weeks prior to enrollment without new onset proteinuria Calculated glomerular filtration rate (cGFR) ≥30 and ≤75 mL/min/1.73 m2 [Modification of Diet in Renal Disease study (MDRD) 4formula] Recipients with EpsteinBarr virus (EBV) serostatus negative or unknown History of acute rejection (AR) within 3 months prior to enrollment History of antibody mediated rejection Positive Tcell lymphocytotoxic cross match Proteinuria &gt;1 g/day or &gt;0.5 g/day if diabetic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>